Abstract:Abstract Background Imatinib combined with chemotherapy for induction and intensification therapy has become the standard strategy for Philadelphia-positive acute lymphocytic leukemia (Ph+ALL). Anyhow, intensified chemotherapy lead to about 5% of early death. Because we believed that imatinib plays the most important role in Ph+ALL treatment, we started Ph+ALL-HX-200803 trial (WHO ICTRP Registry No. ChiCTR-TNRC-00000309 ) to test the effect of combining imatinib and low dose chemotherapy and added interferon-¦Á in maintenance to prevent relapse. Method According to our protocol, all patients received imatinib 400mg daily, vindesine 4 mg weekly and dexamethasone 10mg/m2/day for 4 days per week for 4 weeks as induction therapy. For patients under 55 years old, we give them three sequential courses of intensified chemotherapy (CAM, high dose MTX+L-Asp, and MA, CALLG2008 protocol). Patients in CR1 would receive allogenic HSCT if they had suitable donors. Those who were reluctant to receive or unsuitable for allo-HSCT received maintenance therapy with imatinib 400mg daily, interferon-¦Á 3 million unit 2-3 doses per week and chemotherapy. Maintenance chemotherapy including vindesine and dexamethasone was given monthly in the first year, once every two months in the second year, and once every three months in the third year. For patients over 55 years old, we skipped intensified chemotherapy and gave them maintenance therapy directly. Minimal residual disease surveillance was conducted by BCR/ABL fusion gene quantification. The main endpoints were 3-year overall survival and disease free survival. Result Between 2008 and 2012, 50 patients with newly diagnosed Ph+ALL were enrolled. The median age of this group of patients was 35.5 years old. All but one patients achieved complete remission (98%) after 4 weeks induction therapy. No patient died during induction therapy. The median follow-up time was 27 months. The estimated 3-year DFS and OS were 38.8 ±9.2% and 52.7±10.4%. Five patients received allo-HSCT in CR1. For patients who did not receive allo-HSCT in CR1, 1 patient survived for more than 5 years, 7 patients survived for more than 3 years. In post-hoc analysis, patients achieved MRD negativity at six month showed better median DFS (not reached vs. 11 moths, p=0.001) and OS (not reached vs. 22 months, p=0.015) compared to those who did not. Conclusion The outcomes of our study suggest that imatinib combing with low dose chemotherapy showed a high and safe induction remission rate, combination of interferon-¦Á with imatinib and maintenance chemotherapy might improve the outcomes of patients with Ph+All who were not eligible for Allo-HSCT. MRD status at six month is an important prognostic indicator. The long term disease-free survivors may signal the possibility of a cure even without allo-HSCT. Disclosures: No relevant conflicts of interest to declare.

Impact of a guaranteed access program to imatinib on the survival of patients with chronic myeloid leukemia

Combination Imatinib With Interferon-Alpha For Philadelphia Positive Acute Lymphocytic Leukemia: A Multiple Centers Study In China

Efficacy and Safety of Generic Imatinib in Chronic Phase of Chronic Myeloid Leukemia (CP-CML): Experience from a Multi-Center in China

Application of Imatinib Plus Hyper-CVAD Chemotherapy Regimen in Patients with Ph Chromosome Positive Acute Lymphocytic Leukemia

Investigation of Long-Term Follow-Up Results of 135 Patients with Chronic Myeloid Leukemia Receiving Imatinib

[Analysis of Efficacy and Related Factors in 85 Chronic Myeloid Leukemia Patients Treated with Imatinib Mesylate].

Efficacy and safety of adjuvant post-surgical therapy with imatinib in gastrointestinal stromal tumor patients with high risk of recurrence: interim analysis from a multicenter prospective clinical trial]

Treatment Access for Gastrointestinal Stromal Tumor in LMICs

The Impact of Non-Compliance with Imatinib (IM) Therapy on Health Care Costs.

Healthcare Resource Utilization and Costs Associated with Non-Adherence to Imatinib Treatment in Chronic Myeloid Leukemia Patients.

[The Efficacy of Imatinib Mesylate for 124 Patients with Chronic Myeloid Leukemia in Accelerated and Blastic Phase].

Efficacy and safety evaluation of imatinib mesylate for chronic granulocytic leukemia patients in chronic phase: a 4.5-year follow-up of 100 cases

[Efficacy and Safety Evaluation of Imatinib in the Treatment of Patients with Chronic Granulocytic Leukemia in Accelerated Phase].

Administration of Imatinib after Allogeneic Hematopoietic Stem Cell Transplantation May Improve Disease-Free Survival for Patients with Philadelphia Chromosome-Positive Acute Lymphobla Stic Leukemia

A comparative study of different intervention regimens for chronic myelogenous leukemia post allogeneic hematopoietic stem cell transplantation

Real-world Imatinib Mesylate Treatment in Patients with Chronic Myeloid Leukemia: The Importance of Molecular Monitoring and the Early Molecular Response

Imatinib Mesylate Versus Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Chronic Myelogenous Leukemia in the Accelerated Phase

Imatinib with intensive chemotherapy in AML with t(9;22)(q34.1;q11.2)/BCR::ABL1. A DATAML registry study

Comparison of Response over 6 Years Between Patients with Chronic Myeloid Leukemia Who Received Imatinib As Initial Therapy and Those Who Received Imatinib As Secondary Therapy.

Comparable Efficacy and Safety of Generic Imatinib and Branded Imatinib in Patients with Newly Diagnosed Chronic Myeloid Leukemia with a Consideration of Socioeconomic Characteristics: A Retrospective Study from a Single Center.

Real-World Study Of Imatinib Treatment Patterns And Outcomes Among Veteran Patients With Chronic Myeloid Leukemia